What question did this study set out to answer?

The trial aims to determine if combining pulmonary artery denervation with guideline-directed medical therapy better reduces clinical worsening in patients with pulmonary hypertension from left-sided heart failure.

January 10, 2026Cardiology DiscoveryOpen Access

Pulmonary Artery Denervation for the Treatment of Patients With Pulmonary Hypertension Secondary to Left-Sided Heart Failure: Rationale and Design of the Randomized Controlled PADN-HF-PH Trial

Q: What does this research mean for the field?

Combining pulmonary artery denervation with guideline-directed medical therapy can reduce clinical worsening in patients with pulmonary hypertension due to heart failure. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

View Full Paper

Ask AI

Bookmark

Key result

Trial tests if adding PADN to GDMT reduces clinical worsening in PH due to HF.

Why the study?

It remains uncertain whether combined pulmonary artery denervation and guideline-directed medical therapy can effectively reduce clinical worsening in patients with heart failure and pulmonary hypertension associated with left heart disease.

Does pulmonary artery denervation added to guideline-directed medical therapy reduce clinical worsening in patients with pulmonary hypertension secondary to left-sided heart failure?

Population

264 subjects with PH secondary to left-sided HF despite GDMT

Comparison

PADN plus GDMT vs GDMT alone

Design

Prospective multicenter superiority randomized controlled trial

Follow-up

At least 6 months

Authors

QWQiguang WangGeneral Hospital of Shenyang Military Region JZJuan ZhangNanjing Medical University HZHang ZhangNanjing Medical University

Discussion

Member takes

Implication

PADN plus GDMT should not yet alter PH-HF management; RCT leaves open its effect on clinical worsening.

Key Points

The trial aims to determine if combining pulmonary artery denervation with guideline-directed medical therapy better reduces clinical worsening in patients with pulmonary hypertension from left-sided heart failure.
Prospective, multicenter, randomized controlled trial design.
264 subjects with pulmonary hypertension secondary to left-sided heart failure.
Participants randomized 1:1 to either PADN plus GDMT or GDMT alone.
Stratification by pulmonary hypertension phenotypes and sites.
Primary endpoint assesses composite outcomes including death, rehospitalization, and worsening heart failure.
The effectiveness of PADN combined with GDMT on clinical outcomes is under evaluation.
The primary endpoint includes serious clinical events such as rehospitalization and mortality.
Safety data will report incidence of adverse events within 30 days post-PADN procedure.

Structured PICO

Does pulmonary artery denervation added to guideline-directed medical therapy reduce clinical worsening in patients with pulmonary hypertension secondary to left-sided heart failure?

Population

264 subjects with pulmonary hypertension (PH) secondary to left-sided heart failure (HF) despite guideline-directed medical therapy (GDMT)

Intervention

Pulmonary artery denervation (PADN) plus guideline-directed medical therapy (GDMT)

Comparator

Guideline-directed medical therapy (GDMT) alone

Outcome

Composite of all-cause death, rehospitalization due to HF, requirement for intravenous medication (inotropes, diuretics, or vasodilators) due to worsening of HF, referral for heart/lung transplantation, or 6-minute walk distance decreased by >10% or >30 m compared with baseline when the last enrolled subject has at least 6 months of follow-upcomposite

The PADN-HF-PH trial will determine if pulmonary artery denervation added to standard therapy improves clinical outcomes in patients with pulmonary hypertension secondary to left-sided heart failure.

Cite This Study

Wang et al. (2026) studied this question. The trial aims to determine if combining pulmonary artery denervation with guideline-directed medical therapy can reduce clinical worsening in patients with pulmonary hypertension due to heart failure.

synapsesocial.com/papers/696321c091e05aa366cb7fce https://doi.org/10.1097/cd9.0000000000000181

Topics

HFrEF treatment Heart failure Artificial intelligence in cardiology HFpEF management

View Full Paper

Ask AI

Bookmark

Pulmonary Artery Denervation for the Treatment of Patients With Pulmonary Hypertension Secondary to Left-Sided Heart Failure: Rationale and Design of the Randomized Controlled PADN-HF-PH Trial

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Topics

Pulmonary Artery Denervation for the Treatment of Patients With Pulmonary Hypertension Secondary to Left-Sided Heart Failure: Rationale and Design of the Randomized Controlled PADN-HF-PH Trial

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider